• Home
  • Therapy Pipeline
    • Immuno-Oncology
    • Pain
  • Research
  • Team
    • Management
    • Board Directors
    • Scientific and Clinical Advisors and Collaborators
  • News
  • About
    • Contact Us
    • About Us
  • More
    • Careers
    • Internship
    • Partnering
Syntrix Pharmaceuticals
Syntrix Pharmaceuticals Syntrix Pharmaceuticals Syntrix Pharmaceuticals
  • Home
  • Therapy Pipeline
    • Immuno-Oncology
    • Pain
  • Research
  • Team
    • Management
    • Board Directors
    • Scientific and Clinical Advisors and Collaborators
  • News
  • About
    • Contact Us
    • About Us
  • More
    • Careers
    • Internship
    • Partnering
    • Login
    • Sign Up

Blog

Syntrix Pharmaceuticals > Blog
  • News

    Syntrix to Collaborate with NCI to Study SX-682 – Cooperative Research and Development Agreement (CRADA) Assesses SX-682 Alone and In Various Combinations

    June 16, 2017 - by Syntrix

    Syntrix today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute…

    Read more
    0
    Syntrix
  • News

    Syntrix Receives $2.3M Grant to Conduct a Phase 1/2 Clinical Trial Evaluating SX-682 Alone and with Pembrolizumab in Metastatic Melanoma

    May 4, 2017 - by Syntrix

    Syntrix announced today the award of a $2.3 million grant from the National Cancer Institute (NCI) of the National Institutes…

    Read more
    0
    Syntrix
  • News

    Study Published in Nature Provides Path for New Immunotherapy to Prostate Cancer Using SX-682 – Results Underpin Clinical Trial of SX-682 With Anti-PD1 and Anti-CTLA4 Combination

    March 30, 2017 - by Syntrix

    Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, is made “hot” by the addition of SX-682,…

    Read more
    0
    Syntrix
  • News

    Syntrix Wins U.S. Patent 9,480,694 – Thiopyrimidinecarboxamide for Use in Treating Pulmonary Disease

    November 1, 2016 - by Syntrix

    Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean…

    Read more
    0
    Syntrix
  • News

    Syntrix Receives $2.965M Grant to Conduct a Phase Ib Clinical Trial Investigating Omnitram for the Treatment of Pain in Patients Resistant to Tramadol

    August 22, 2016 - by Syntrix

    Syntrix announced today the award of a $2.965 million grant from the National Institute on Drug Abuse (NIDA) of the…

    Read more
    3
    Syntrix
  • News

    Syntrix to Present at the 2016 Needham & Company 15th Annual Healthcare Conference

    April 11, 2016 - by Syntrix

    Syntrix today announced that John A. Zebala, M.D., PhD, President and Chief Executive Officer, is scheduled to present at the…

    Read more
    0
    Syntrix
  • News

    Syntrix Opens Investigational New Drug (IND) Application for SX-682, a Dual CXCR1 and CXCR2 Inhibitor

    April 7, 2016 - by Syntrix

    Syntrix today announced that it has opened an Investigational New Drug (IND) application with the U.S. Food and Drug Administration…

    Read more
    0
    Syntrix
  • News

    Syntrix publication in Bioorganic & Medicinal Chemistry Letters

    September 15, 2015 - by Syntrix

    Congratulations to Syntrix scientists on their latest publication, which appeared in the journal Bioorganic & Medicinal Chemistry Letters.  Abstract: The…

    Read more
    0
    Syntrix
  • News

    Syntrix Receives $1.725M Grant to Conduct a Phase II Clinical Trial Investigating Omnitram for the treatment of Diabetic Neuropathic Pain

    August 3, 2015 - by Syntrix

    Syntrix announced today the award of a $1.725 million grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to perform a clinical study investigating the

    Read more
    3
    Syntrix
  • News

    Syntrix wins U.S. patent 8,748,623: Pyridinecarboxamides as CXCR2 modulators

    June 10, 2015 - by Syntrix

    Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean…

    Read more
    0
    Syntrix
  • News

    Syntrix Publication in Bioorganic & Medicinal Chemistry Letters

    April 23, 2015 - by Syntrix

    Congratulations to Syntrix scientists on their latest publication, which appeared in the journal Bioorganic & Medicinal Chemistry Letters.  Abstract: Blockade of undesired neutrophil migration to sites of inflammation remains an area of substantial pharmaceutical interest….

    Read more
    2
    Syntrix
  • News

    Syntrix Wins U.S. Patent 9,000,142: Photocleavable Sense-Antisense Complex

    April 7, 2015 - by Syntrix

    Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventor:  Zebala; John…

    Read more
    2
    Syntrix
  • News

    Syntrix Wins U.S. Patent 8,993,541: Aminopyrimidine Carboxamides as CXCR2 Modulators

    March 31, 2015 - by Syntrix

    Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean…

    Read more
    1
    Syntrix
  • News

    Syntrix wins U.S. patent 8,981,106: Pyrimidinecarboxamides as CXCR2 modulators

    March 17, 2015 - by Syntrix

    Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean…

    Read more
    0
    Syntrix
  • News

    Syntrix wins U.S. patent 8,969,365: Thiopyrimidinecarboxamides as CXCR1/2 modulators

    March 3, 2015 - by Syntrix

    Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean…

    Read more
    0
    Syntrix
  • News

    Syntrix publication in Journal of Medicinal Chemistry

    October 23, 2014 - by Syntrix

    Congratulations to Syntrix scientists on their latest publication, which appeared in the ACS Journal of Medicinal Chemistry.  Abstract: The G…

    Read more
    5
    Syntrix
  • News

    Syntrix wins U.S. patent 8,779,149: Aminopyridine and aminopyrimidine carboxamides as CXCR2 modulators

    July 15, 2014 - by Syntrix

    Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office.  Inventors: Maeda, Dean…

    Read more
    0
    Syntrix
  • News

    Syntrix featured in the NIH Innovation Zone at 2014 Bio International Convention in San Diego, CA

    June 26, 2014 - by Syntrix

    Syntrix was selected by the NIH to host a kiosk in the Innovation Zone, an area dedicated to showcasing Small…

    Read more
    0
    Syntrix
  • 1
  • 2

Syntrix Pharmaceuticals
215 Clay Street NW
Suite B-5
Auburn, WA  98001

©2025 All Rights Reserved

NIH Required Policy for Managing Conflicts of Significant Financial Interest

Recent Articles

  • Syntrix to present at 2025 Life Science Innovation Northwest (LSINW)
  • ASCO 2024 selects SX-682 for oral podium presentation of positive first-in-class efficacy results in patients with metastatic melanoma
  • Home
  • Team
  • Research
  • Therapy Pipeline
    • Pain
    • Immuno-Oncology
  • Apply

Get in touch

TEL: 253-833-8009
FAX: 253-833-8127 email: info@syntrixbio.com